ANI Pharmaceuticals
ANIP

$63.25

1.97%

Market Cap: 1.33B

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 642

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 24

30% more capital invested

Capital invested by funds: $750M [Q4 2023] → $974M (+$224M) [Q1 2024]

23% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 53

10% more funds holding

Funds holding: 181 [Q4 2023] → 199 (+18) [Q1 2024]

0.41% more ownership

Funds ownership: 66.55% [Q4 2023] → 66.95% (+0.41%) [Q1 2024]

91% less call options, than puts

Call options by funds: $3.41M | Put options by funds: $39.2M

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$72

14%

upside

Avg. target

$81

29%

upside

High target

$94

49%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Oren Livnat	49%upside $94	Buy Maintained	26 Jun 2024
HC Wainwright & Co. Oren Livnat	38%upside $87	Buy Maintained	13 May 2024
Guggenheim Vamil Divan	22%upside $77	Buy Reiterated	23 Apr 2024
Guggenheim Vamil Divan	22%upside $77	Buy Maintained	5 Mar 2024
HC Wainwright & Co. Oren Livnat	31%upside $83	Buy Maintained	4 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ANIP published over the past 30 days

ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine Oral Powder is the generic version of the reference listed drug (RLD) Endari®.

ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP. ANI's Naproxen Delayed-Release Tablets is the generic version of the reference listed drug (RLD) EC-Naprosyn®.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon th.

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.

ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner

Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact

ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue Adds two commercial assets ILUVIEN ® and YUTIQ ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafter Expected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from accelerated growth of Purified Cortrophin ® Gel in ophthalmology Increased geographic diversification with Alimera's established ex-US footprint, including direct operations in Europe PRINCETON, N.J.

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales.

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference

BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows:

ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)

NEW YORK , May 20, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on behalf of the company's shareholders. The investigation seeks to determine whether ANI Pharmaceuticals's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)

Zacks Investment Research

Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround

ANI (ANIP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround

See News Rankings